Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dosage in low-dose heparin prophylaxis.

J Seglias, U F Gruber

    Haemostasis
    |January 1, 1979
    PubMed
    Summary
    This summary is machine-generated.

    Higher doses of subcutaneous heparin (3 x 5,000 U/day) appear more effective in preventing deep venous thrombosis (DVT) and fatal pulmonary emboli after surgery. Lower doses showed some benefit, but higher doses demonstrated greater efficacy and similar safety profiles.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Animal models.

    American journal of industrial medicine·1994
    Same author

    Asbestos fibers in parenteral medication.

    Regulatory toxicology and pharmacology : RTP·1993
    Same author

    [Glass fiber pneumoconiosis].

    Der Pathologe·1993
    Same author

    Linkage between rheumatoid arthritis susceptibility and the presence of HLA-DR4 and DR beta allelic third hypervariable region sequences in southern Chinese persons.

    Arthritis and rheumatism·1992
    Same author

    Carcinogenicity of the insulation wools: reassessment of the IARC evaluation.

    Regulatory toxicology and pharmacology : RTP·1991
    Same author

    Comparisons of spontaneous pain and tenderness in patients with primary fibromyalgia.

    Clinical rheumatology·1991
    Same journal

    Thrombosis and Haemostasis Issues in Cancer. International Conference. Bergamo, Italy, 2-4 November 2001. Lectures and abstracts.

    Haemostasis·2002
    Same journal

    Biochemistry of cancer procoagulant.

    Haemostasis·2002
    Same journal

    Management of thromboembolic disease in cancer patients.

    Haemostasis·2002
    Same journal

    An overview of thromboprophylaxis in malignancy.

    Haemostasis·2002
    Same journal

    Platelets cross-talk with tumor cells.

    Haemostasis·2002
    Same journal

    Properties and function of heparanase in cancer metastasis and angiogenesis.

    Haemostasis·2002
    See all related articles

    Area of Science:

    • Medical research
    • Pharmacology
    • Thromboembolism prophylaxis

    Background:

    • Subcutaneous heparin is used for postoperative thromboembolism prophylaxis.
    • The optimal dosage for efficacy and safety is debated.

    Purpose of the Study:

    • To investigate if heparin dosage influences efficacy in preventing postoperative thromboembolism.
    • To compare the effectiveness of 5,000 U twice daily versus three times daily subcutaneous heparin.

    Main Methods:

    • Systematic review of prospective, controlled, comparative, or randomized studies.
    • Analysis of studies using heparin 5,000 U b.i.d. or t.i.d. subcutaneously.
    • Inclusion of data from general, gynecological, urological, chest, and orthopedic/traumatic surgeries.

    Related Experiment Videos

    Main Results:

    • Higher heparin dosage (3 x 5,000 U/day) significantly reduced deep venous thrombosis (DVT) frequency in major surgeries compared to lower dosage (2 x 5,000 U/day).
    • The higher dosage was associated with a reduction in fatal pulmonary emboli, while the lower dosage did not provide sufficient evidence.
    • Hemorrhagic complications showed no correlation with body weight or malignant tumor presence, and no significant difference between heparin dosages.

    Conclusions:

    • The higher dosage of subcutaneous heparin (3 x 5,000 U/day) is more effective for preventing postoperative deep venous thrombosis and fatal pulmonary emboli.
    • Both dosages demonstrated similar safety profiles regarding hemorrhagic complications.
    • Further research may be needed to confirm efficacy in specific surgical populations, especially orthopedic/traumatic surgery.